<DOC>
	<DOCNO>NCT02566889</DOCNO>
	<brief_summary>The purpose study evaluate whether trough serum infliximab concentration time loss clinical response identify pediatric participant inflammatory bowel disease ( IBD ) would benefit ( regain clinical response ) dose escalation currently approve dose [ 5 milligram ( mg ) /kilogram ( kg ) every 8 week ( q8wk ) ] .</brief_summary>
	<brief_title>An Efficacy Safety Study Infliximab Pediatric Participants With Inflammatory Bowel Disease</brief_title>
	<detailed_description>This multicenter ( one hospital medical school team work medical research study ) , prospective ( study follow participant forward time ) , open-label ( people know identity intervention ) study infliximab pediatric participant inflammatory bowel disease . The study consist 3 Phases : screening Phase ( 2 Weeks ) , open-label treatment Phase ( 56 Weeks ) follow safety Phase ( 8 Weeks ) . The duration participation study participant approximately 66 Weeks ( include screen period ) . Participants ' efficacy safety outcomes monitor throughout study .</detailed_description>
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Must biopsyconfirmed diagnosis Crohn 's disease ( CD ) ulcerative colitis ( UC ) prior study entry Must meet concomitant medication stability criterion specify protocol Is consider eligible accord tuberculosis ( TB ) Screening criterion specify protocol Must negative stool result enteric pathogen . Stool study must include stool culture Clostridium difficile toxin assay . These must perform Screening current episode disease exacerbation long stool study perform within 4 month prior first administration infliximab Week 0 Must date immunization agreement current local immunization guideline immunosuppressed participant prior Screening Must discontinue infliximab therapy Must require , must require , within 2 month prior Screening , surgery active gastrointestinal bleeding , peritonitis , intestinal obstruction , intraabdominal pancreatic abscess require surgical drainage , condition possibly confound evaluation benefit infliximab treatment Must presence history colonic small bowel obstruction within 6 month prior Screening , confirm objective radiographic endoscopic evidence stricture result obstruction ( example , dilation colon small bowel proximal stricture barium radiograph inability traverse stricture endoscopy ) Must local manifestation CD , fistula , stricture , abscess , disease complication surgery might indicate . Enterocutaneuous fistula surgery indicate , allow Must presence stoma Must document short bowel syndrome ( 100 centimeter total small bowel resect )</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Pediatric Inflammatory Bowel Disease</keyword>
	<keyword>Infliximab</keyword>
	<keyword>Pediatric Participants</keyword>
	<keyword>Pediatric Ulcerative Colitis</keyword>
	<keyword>Pediatric Crohn 's Disease</keyword>
	<keyword>Dose Escalation</keyword>
</DOC>